Dissolvable film BNT23001 led to about 40% higher cladribine exposure than tablets in a preclinical pig study, BioNxt ...
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig study ...
The latest update is out from BioNxt Solutions ( (TSE:BNXT) ).
Credit: Tonix Pharmaceuticals. Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia. Clinical trials have demonstrated that Tonmya reduces ...
CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF ...
Buprenorphine sublingual tablet is prescribed to treat opioid use disorder in two phases: an induction phase to manage initial withdrawal symptoms and a maintenance phase for long-term treatment. You ...
Discover how iX Biopharma's patented drug delivery technology is driving its growth and expanding its product portfolio ...
Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020 Topline Results of Approximately 470 Participants with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results